JatrorrhizineCAS# 3621-38-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 3621-38-3 | SDF | Download SDF |
PubChem ID | 72323 | Appearance | Yellow powder |
Formula | C20H20NO4 | M.Wt | 338.4 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol | ||
SMILES | COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)O)OC)OC | ||
Standard InChIKey | MXTLAHSTUOXGQF-UHFFFAOYSA-O | ||
Standard InChI | InChI=1S/C20H19NO4/c1-23-18-5-4-12-8-16-14-10-19(24-2)17(22)9-13(14)6-7-21(16)11-15(12)20(18)25-3/h4-5,8-11H,6-7H2,1-3H3/p+1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Jatrorrhizine has neuroprotective, antioxidative, anti-inflammatory, antihypercholesterolemic, and anti-hyperglycemia effects.Jatrorrhizine is expected to be developed as a new gastric prokinetic drug, it is metabolized by human CYP1A2 and multiple UGT1A isoforms. It has inhibitory activities against the expression of inducible NO syntase (iNOS) and cyclooxygenase-2 (COX-2), and can improve the utilization and excretion of cholesterol by up-regulating the mRNA and protein expression of LDLR and CYP7A1. |
Targets | LDL | P450 (e.g. CYP17) | NOS | COX | 5-HT Receptor | HMG-CoA Reductase |
In vitro | Anti-inflammatory Effect of Jatrorrhizine from Phellodendron amurense in Lipopolysaccharide-stimulated Raw264.7 Cells.[Reference: WebLink]J.Appl.Biol. Chem.,2011,54(2):.114-9.n-Butanol extracts from Phellodendron amurense have about 50% inhibitory activity against hyaluronidase. |
In vivo | The antihypercholesterolemic effect of jatrorrhizine isolated from Rhizoma Coptidis.[Pubmed: 24894270]Phytomedicine. 2014 Sep 25;21(11):1373-81.
Effect of jatrorrhizine on delayed gastrointestinal transit in rat postoperative ileus.[Pubmed: 22309273 ]J. Pharm. Pharmacol., 2012, 64(3):413-9.Postoperative ileus is major cause of postoperative complication and prolonged hospitalization. Jatrorrhizine, which is a protoberberine alkaloid isolated from the medicinal plants Berberis aristata and Coptis chinensis, has been found to increase contractility of gastric antral and ileum smooth muscles of rat gastrointestinal tract. We have investigated whether Jatrorrhizine could offset gastrointestinal transit in rat with postoperative ileus.
|
Kinase Assay | CYP450 1A2 and multiple UGT1A isoforms are responsible for jatrorrhizine metabolism in human liver microsomes.[Pubmed: 23299247 ]Biopharm Drug Dispos. 2013 Apr;34(3):176-85.Jatrorrhizine, one of the protoberberine alkaloids derived from the plant Coptis chinensis, is expected to be developed as a new gastric prokinetic drug, but its metabolic characteristics in humans remain unknown. |
Animal Research | Effect of jatrorrhizine, berberine, Huanglian Decoction and compound-mimic prescription on blood glucose in mice.[Reference: WebLink]Chinese Traditional & Herbal Drugs, 2005, 36(4):548-51.To study the hypoglycemic activity of Jatrorrhizine (Jat) and compare the effects of Jat, berberine (Ber), Huanglian Decoction (HLD), and compounds-mimic prescription (Ber+Jat) on blood glucose level in mice. |
Jatrorrhizine Dilution Calculator
Jatrorrhizine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.9551 mL | 14.7754 mL | 29.5508 mL | 59.1017 mL | 73.8771 mL |
5 mM | 0.591 mL | 2.9551 mL | 5.9102 mL | 11.8203 mL | 14.7754 mL |
10 mM | 0.2955 mL | 1.4775 mL | 2.9551 mL | 5.9102 mL | 7.3877 mL |
50 mM | 0.0591 mL | 0.2955 mL | 0.591 mL | 1.182 mL | 1.4775 mL |
100 mM | 0.0296 mL | 0.1478 mL | 0.2955 mL | 0.591 mL | 0.7388 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Columbamine
Catalog No.:BCN2722
CAS No.:3621-36-1
- NVP 231
Catalog No.:BCC4244
CAS No.:362003-83-6
- 2-Methoxyestradiol (2-MeOE2)
Catalog No.:BCC2228
CAS No.:362-07-2
- Genistein 7,4'-di-O-beta-D-glucopyranoside
Catalog No.:BCN7835
CAS No.:36190-98-4
- 3'-O-Methylorobol
Catalog No.:BCN5318
CAS No.:36190-95-1
- 3-Acetyl-2,5-dichlorothiophene
Catalog No.:BCC8602
CAS No.:36157-40-1
- Blumenol B
Catalog No.:BCN5317
CAS No.:36151-01-6
- Kobusin
Catalog No.:BCN7563
CAS No.:36150-23-9
- Dehydroleucodine
Catalog No.:BCN6897
CAS No.:36150-07-9
- Saxalin
Catalog No.:BCC8357
CAS No.:36150-06-8
- Mullilam diol
Catalog No.:BCN5316
CAS No.:36150-04-6
- Phytin
Catalog No.:BCN1285
CAS No.:3615-82-5
- Cyclo(D-Leu-L-Pro)
Catalog No.:BCN4028
CAS No.:36238-67-2
- TC 1
Catalog No.:BCC7450
CAS No.:362512-81-0
- (±)-SLV 319
Catalog No.:BCC7954
CAS No.:362519-49-1
- Clemaphenol A
Catalog No.:BCN7834
CAS No.:362606-60-8
- Pitolisant
Catalog No.:BCC1862
CAS No.:362665-56-3
- Pitolisant oxalate
Catalog No.:BCC1864
CAS No.:362665-57-4
- Hederasaponin B
Catalog No.:BCN1085
CAS No.:36284-77-2
- Prostaglandin E2
Catalog No.:BCC7316
CAS No.:363-24-6
- Broussonol E
Catalog No.:BCN7996
CAS No.:363134-28-5
- Piroxicam
Catalog No.:BCC3841
CAS No.:36322-90-4
- YL-109
Catalog No.:BCC5543
CAS No.:36341-25-0
- Cyclo(L-Ala-L-Pro)
Catalog No.:BCN4012
CAS No.:36357-32-1
The antihypercholesterolemic effect of jatrorrhizine isolated from Rhizoma Coptidis.[Pubmed:24894270]
Phytomedicine. 2014 Sep 25;21(11):1373-81.
Current work was conducted to evaluate the safety and antihypercholesterolemic activity of Jatrorrhizine extracted from Rhizoma Coptidis (RC) and its potential mechanism on regulating cholesterol metabolism. It was found that the LD50 of Jatrorrhizine in mice was more than 5,500 mg/kg and there were no influences on clinical signs, organ weight changes, urinalysis and hematological parameters, gross necropsy and histological alterations in Jatrorrhizine-treated rats during the 3-month period, compared to the control group. Jatrorrhizine showed a strong lipid-lowering effect in a dose-dependent manner. Oral administration of 70.05 mg/kg of Jatrorrhizine on Mesocricetus auratus (Syrian golden hamsters) exhibited significant decrease in TC, TG, and LDL-c levels by 20%, 43%, and 19%, respectively, and increase in HDL-c and total bile acids (TBA) content in feces (p<0.01), compared to high-fat and high-cholesterol (HFHC) group. Besides, Jatrorrhizine dose-dependently slowed the rate of weight gain. The results of qRT-PCR, western blotting and ELISA revealed that Jatrorrhizine significantly up-regulated the mRNA and protein expression of LDLR and CYP7A1, but exhibited no significant effect on mRNA and protein expression of HMGR and ASBT in hamsters. In conclusion, Jatrorrhizine was a safe and potential antihypercholesterolemic agent from RC which could improve the utilization and excretion of cholesterol by up-regulating the mRNA and protein expression of LDLR and CYP7A1.
Effect of jatrorrhizine on delayed gastrointestinal transit in rat postoperative ileus.[Pubmed:22309273]
J Pharm Pharmacol. 2012 Mar;64(3):413-9.
OBJECTIVES: Postoperative ileus is major cause of postoperative complication and prolonged hospitalization. Jatrorrhizine, which is a protoberberine alkaloid isolated from the medicinal plants Berberis aristata and Coptis chinensis, has been found to increase contractility of gastric antral and ileum smooth muscles of rat gastrointestinal tract. We have investigated whether Jatrorrhizine could offset gastrointestinal transit in rat with postoperative ileus. METHODS: Postoperative ileus was induced by laparotomy with intestinal manipulation under anaesthesia. Gastrointestinal transit was evaluated by measurement of gastric emptying, geometric centre and the migration of Evans blue. KEY FINDINGS: Postoperative ileus significantly delayed gastric emptying and intestinal transit. Jatrorrhizine dose-dependently (0.1, 0.3 and 1 mg/kg) offset delayed gastric emptying and intestinal transit (geometric centre and the migration of Evans blue) in postoperative ileus. Pretreatment of animals with atropine inhibited the action of Jatrorrhizine on gastric emptying and intestinal transit, but pretreatment of animals with SB204070 did not influence the effect of Jatrorrhizine on gastric emptying and intestinal transit in postoperative ileus. CONCLUSIONS: Jatrorrhizine offset postoperative ileus-induced delayed gastric emptying and intestinal transit in rats, an action mediated via the cholinergic pathway, but not involving activation of 5-HT(4) receptors.
CYP450 1A2 and multiple UGT1A isoforms are responsible for jatrorrhizine metabolism in human liver microsomes.[Pubmed:23299247]
Biopharm Drug Dispos. 2013 Apr;34(3):176-85.
Jatrorrhizine, one of the protoberberine alkaloids derived from the plant Coptis chinensis, is expected to be developed as a new gastric prokinetic drug, but its metabolic characteristics in humans remain unknown. This study characterized the phase I and phase II metabolites, metabolic kinetics, and cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes responsible for the metabolism of Jatrorrhizine in human liver microsomes (HLMs). Chemical inhibition in HLMs and metabolism by recombinant human CYP or UGT enzymes were employed to determine the key metabolic enzyme subtypes. In HLMs, demethyleneberberine (demethylated product) and Jatrorrhizine glucuronide were identified as the phase I and phase II metabolites, respectively. The enzyme kinetics for both demethylation and glucuronidation were fitted to the Michaelis-Menten equation. Demethylation was inhibited significantly by furafylline and predominantly catalysed by recombinant CYP1A2, whereas glucuronidation was inhibited by silibinin, quercetin, as well as 1-naphthol and catalysed by recombinant UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A9 and UGT1A10. These results showed that Jatrorrhizine is metabolized by human CYP1A2 and multiple UGT1A isoforms.